Tg Therapeutics (TGTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $53.97, -3.62% vs the prior close of $56.00.
- Volume 1.77M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TGTX slides 3.6% to $53.97. Closed at $53.97, -3.62% vs the prior close of $56.00. Day range $53.66–$56.24, opened at $56.00.
TGTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TGTX slides 3.6% to $53.97
- Closed at $53.97, -3.62% vs the prior close of $56.00. Day range $53.66–$56.24, opened at $56.00.
- Volume was 1.77M shares, 1.0x its 50-day average of 1.81M.
- Price is -0.3% vs its 50-day average ($54.14) and +27.0% vs its 200-day average ($42.49).
- 52-week range $26.76–$59.30; today's close sits at 84% of that range, 9.0% below the 52-week high.
Oct 15, 2026 — TGTX rises 3.0% to $56.00
- Closed at $56.00, +3.00% vs the prior close of $54.37. Day range $54.76–$56.83, opened at $55.12.
- Volume was 1.81M shares, 1.0x its 50-day average of 1.83M.
- Price is +3.6% vs its 50-day average ($54.05) and +32.2% vs its 200-day average ($42.37).
- 52-week range $26.76–$59.30; today's close sits at 90% of that range, 5.6% below the 52-week high.
Oct 14, 2026 — TGTX ends flat (+0.1%) to $54.37
- Closed at $54.37, +0.06% vs the prior close of $54.34. Day range $53.36–$55.37, opened at $54.08.
- Volume was 1.29M shares, 0.7x its 50-day average of 1.86M.
- Price is +0.8% vs its 50-day average ($53.93) and +28.7% vs its 200-day average ($42.24).
- 52-week range $26.76–$59.30; today's close sits at 85% of that range, 8.3% below the 52-week high.
Oct 13, 2026 — TGTX dips 1.7% to $54.34
- Closed at $54.34, -1.68% vs the prior close of $55.27. Day range $53.63–$55.39, opened at $55.23.
- Volume was 1.00M shares, 0.5x its 50-day average of 1.97M — lighter than usual.
- Price is +1.0% vs its 50-day average ($53.82) and +29.0% vs its 200-day average ($42.12).
- 52-week range $26.76–$59.30; today's close sits at 85% of that range, 8.4% below the 52-week high.
Oct 12, 2026 — TGTX ends flat (-0.2%) to $55.27
- Closed at $55.27, -0.18% vs the prior close of $55.37. Day range $54.65–$55.86, opened at $55.38.
- Volume was 758.10K shares, 0.4x its 50-day average of 2.00M — lighter than usual.
- Price is +3.0% vs its 50-day average ($53.65) and +31.6% vs its 200-day average ($42.01).
- 52-week range $26.76–$59.30; today's close sits at 88% of that range, 6.8% below the 52-week high.
Oct 9, 2026 — TGTX jumps 3.8% to $55.37, 3 up days in a row
- Closed at $55.37, +3.81% vs the prior close of $53.34. Day range $53.36–$55.46, opened at $53.72.
- Volume was 1.62M shares, 0.8x its 50-day average of 2.03M.
- Price is +3.3% vs its 50-day average ($53.59) and +32.2% vs its 200-day average ($41.88).
- 52-week range $26.76–$59.30; today's close sits at 88% of that range, 6.6% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — TGTX rises 0.7% to $53.34
- Closed at $53.34, +0.74% vs the prior close of $52.95. Day range $52.12–$53.90, opened at $53.34.
- Volume was 1.74M shares, 0.8x its 50-day average of 2.05M.
- Price is -0.4% vs its 50-day average ($53.55) and +27.7% vs its 200-day average ($41.76).
- 52-week range $26.76–$59.30; today's close sits at 82% of that range, 10.1% below the 52-week high.
Oct 7, 2026 — TGTX rises 1.5% to $52.95
- Closed at $52.95, +1.46% vs the prior close of $52.19. Day range $51.40–$53.88, opened at $51.83.
- Volume was 1.51M shares, 0.7x its 50-day average of 2.07M.
- Price is -1.1% vs its 50-day average ($53.56) and +27.1% vs its 200-day average ($41.65).
- 52-week range $26.76–$59.30; today's close sits at 80% of that range, 10.7% below the 52-week high.
Oct 6, 2026 — TGTX slides 3.2% to $52.19, a 1-month low
- Closed at $52.19, -3.19% vs the prior close of $53.91. Day range $51.34–$54.11, opened at $54.11.
- Volume was 2.41M shares, 1.2x its 50-day average of 2.05M.
- Price is -2.6% vs its 50-day average ($53.59) and +25.6% vs its 200-day average ($41.54).
- 52-week range $26.76–$59.30; today's close sits at 78% of that range, 12.0% below the 52-week high.
Oct 5, 2026 — TGTX dips 0.7% to $53.91
- Closed at $53.91, -0.70% vs the prior close of $54.29. Day range $53.32–$54.75, opened at $54.35.
- Volume was 1.55M shares, 0.8x its 50-day average of 2.05M.
- Price is +0.5% vs its 50-day average ($53.66) and +30.1% vs its 200-day average ($41.43).
- 52-week range $26.76–$59.30; today's close sits at 83% of that range, 9.1% below the 52-week high.
Oct 2, 2026 — TGTX rises 1.2% to $54.29
- Closed at $54.29, +1.25% vs the prior close of $53.62. Day range $53.15–$54.98, opened at $54.17.
- Volume was 1.65M shares, 0.8x its 50-day average of 2.08M.
- Price is +1.1% vs its 50-day average ($53.71) and +31.4% vs its 200-day average ($41.32).
- 52-week range $26.76–$59.30; today's close sits at 85% of that range, 8.4% below the 52-week high.
TGTX latest news & SEC filings
Every SEC filing by or about TGTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Charney Laurence N sold 5,000 shares at $54.96 (≈$274.80K) on Sep 10, 2026
- Charney Laurence N sold 5,000 shares at $54.96 (≈$274.80K) on Sep 10, 2026
- Charney Laurence N sold 5,000 shares at $54.96 (≈$274.80K) on Sep 10, 2026
- Charney Laurence N sold 5,000 shares at $54.96 (≈$274.80K) on Sep 10, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 10, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $240.34M (prior year $141.15M) (+70.3% vs Jun 30, 2025)
- Net income: $7.78M (prior year $28.19M) (-72.4% vs Jun 30, 2025)
- Diluted EPS: $0.05 (prior year $0.17) (-70.6% vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade TGTX
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 26, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.76% (largest 3.9%).
- Liquidity: about 1.65M shares (≈$88.95M) trade per day on average.
- 52-week position: $53.97 vs a range of $26.76–$59.30 (84% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Laurence N Charney sold 5,000 shares on Sep 10, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 3, 2026; 8-K Jun 12, 2026.
- Share count: 153.07M shares outstanding (Aug 3, 2026), -3.5% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TGTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 56.00 | 56.24 | 53.66 | 53.97 | 1.77M |
| Oct 15, 2026 | 55.12 | 56.83 | 54.76 | 56.00 | 1.81M |
| Oct 14, 2026 | 54.08 | 55.37 | 53.36 | 54.37 | 1.29M |
| Oct 13, 2026 | 55.23 | 55.39 | 53.63 | 54.34 | 1.00M |
| Oct 12, 2026 | 55.38 | 55.86 | 54.65 | 55.27 | 758.10K |
| Oct 9, 2026 | 53.72 | 55.46 | 53.36 | 55.37 | 1.62M |
| Oct 8, 2026 | 53.34 | 53.90 | 52.12 | 53.34 | 1.74M |
| Oct 7, 2026 | 51.83 | 53.88 | 51.40 | 52.95 | 1.51M |
| Oct 6, 2026 | 54.11 | 54.11 | 51.34 | 52.19 | 2.41M |
| Oct 5, 2026 | 54.35 | 54.75 | 53.32 | 53.91 | 1.55M |
| Oct 2, 2026 | 54.17 | 54.98 | 53.15 | 54.29 | 1.65M |
| Oct 1, 2026 | 55.58 | 56.12 | 53.59 | 53.62 | 2.12M |
| Sep 30, 2026 | 56.41 | 56.98 | 55.35 | 55.78 | 1.91M |
| Sep 29, 2026 | 56.04 | 56.68 | 54.79 | 56.19 | 1.61M |
| Sep 28, 2026 | 57.35 | 57.66 | 55.88 | 56.19 | 1.44M |
| Sep 25, 2026 | 57.97 | 58.69 | 56.61 | 57.43 | 1.31M |
| Sep 24, 2026 | 55.95 | 57.55 | 55.09 | 57.52 | 1.14M |
| Sep 23, 2026 | 58.11 | 58.25 | 54.78 | 56.00 | 2.12M |
| Sep 22, 2026 | 57.41 | 58.62 | 56.56 | 58.11 | 2.08M |
| Sep 21, 2026 | 57.23 | 58.92 | 56.00 | 57.16 | 2.14M |
About Tg Therapeutics
Tg Therapeutics (TGTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1001316.
TGTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Laurence N Charney | Director | Sep 14, 2026 |
| Yann Echelard | Director | Jun 15, 2026 |
| Daniel Hume | Director | Jun 15, 2026 |
| Kenneth Hoberman | Director | Jun 15, 2026 |
| Sagar Lonial | Director | Jun 15, 2026 |
| Michael S Weiss | CEO | Jan 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sean A Power | CFO | Jan 9, 2026 |
| Michael S Weiss | CEO | Jan 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Laurence N Charney | Sale | 5,000 | $54.96 |
| Sep 10, 2026 | Laurence N Charney | Sale | 5,000 | $54.96 |
| Sep 10, 2026 | Laurence N Charney | Sale | 5,000 | $54.96 |
| Sep 10, 2026 | Laurence N Charney | Sale | 5,000 | $54.96 |
| Nov 24, 2025 | Yann Echelard | Sale | 5,000 | $32.57 |
| Nov 24, 2025 | Yann Echelard | Sale | 5,000 | $32.57 |
| Nov 24, 2025 | Yann Echelard | Sale | 5,000 | $32.57 |
| Nov 24, 2025 | Yann Echelard | Sale | 5,000 | $32.57 |
TGTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $616.29M | $447.18M | 2.77 | $-24.77M |
| Dec 31, 2024 | $329.00M | $23.38M | 0.15 | $-40.52M |
| Dec 31, 2023 | $233.66M | $12.67M | 0.09 | $-31.41M |
| Dec 31, 2022 | $2.79M | $-223.81M | -1.65 | $-176.17M |
| Dec 31, 2021 | $6.69M | $-348.10M | -2.63 | $-295.63M |
Latest balance sheet: total assets $1.64B, total liabilities $1.04B, cash $482.57M (as of Jun 30, 2026).
TGTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $46.17 |
| May 6, 2026 | 8-K Item 2.02 (results) | $41.97 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $30.90 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $33.69 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $28.72 |
| May 5, 2025 | 8-K Item 2.02 (results) | $37.68 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $34.42 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $24.36 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 1, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TGTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.